Cost-effectiveness of a new rotavirus vaccination program in Pakistan: A decision tree model

被引:16
|
作者
Patel, Hiten D. [1 ,2 ]
Roberts, Eric T. [3 ]
Constenla, Dagna O. [4 ]
机构
[1] Johns Hopkins Med Inst, James Buchanan Brady Urol Inst, Baltimore, MD 21205 USA
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA
[3] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA
[4] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA
关键词
Rotavirus; Gastroenteritis; Cost-effectiveness; Vaccination; Pakistan; GLOBAL BURDEN; DISEASE; CHILDREN; GASTROENTERITIS; SURVEILLANCE; EFFICACY; HEALTH; IMPACT; IMMUNIZATION; STRATEGIES;
D O I
10.1016/j.vaccine.2013.10.022
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Rotavirus gastroenteritis places a significant health and economic burden on Pakistan. To determine the public health impact of a national rotavirus vaccination program, we performed a cost-effectiveness study from the perspective of the health care system. Methods: A decision tree model was developed to assess the cost-effectiveness of a national vaccination program in Pakistan. Disease and cost burden with the program were compared to the current state. Disease parameters, vaccine-related costs, and medical treatment costs were based on published epidemiological and economic data, which were specific to Pakistan when possible. An annual birth cohort of children was followed for 5 years to model the public health impact of vaccination on health-related events and costs. The cost-effectiveness was assessed and quantified in cost (2012 US$) per disability-adjusted life-year (DALY) averted and cost per death averted. Sensitivity analyses were performed to assess the robustness of the incremental cost-effectiveness ratios (ICERs). Results: The base case results showed vaccination prevented 1.2 million cases of rotavirus gastroenteritis, 93,000 outpatient visits, 43,000 hospitalizations, and 6700 deaths by 5 years of age for an annual birth cohort scaled from 6% current coverage to DPT3 levels (85%). The medical cost savings would be US$1.4 million from hospitalizations and US$200,000 from outpatient visit costs. The vaccination program would cost US$35 million at a vaccine price of US$5.00. The ICER was US$149.50 per DALY averted or US$4972 per death averted. Sensitivity analyses showed changes in case-fatality ratio, vaccine efficacy, and vaccine cost exerted the greatest influence on the ICER. Conclusions: Across a range of sensitivity analyses, a national rotavirus vaccination program was predicted to decrease health and economic burden due to rotavirus gastroenteritis in Pakistan by similar to 40%. Vaccination was highly cost-effective in this context. As discussions of implementing the intervention intensify, future studies should address affordability, efficiency, and equity of vaccination introduction. 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6072 / 6078
页数:7
相关论文
共 50 条
  • [31] Cost-effectiveness analysis of introducing rotavirus vaccine into immunization program in Zhejiang province, China: A decision tree-Markov model study
    Lv, Huakun
    Chen, Fuxing
    Wang, Ying
    Chen, Yaping
    Hu, Yu
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (02)
  • [32] Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland
    Tilson, L.
    Jit, M.
    Schmitz, S.
    Walsh, C.
    Garvey, P.
    McKeown, P.
    Barry, M.
    VACCINE, 2011, 29 (43) : 7463 - 7473
  • [33] Effects of geographic and economic heterogeneity on the burden of rotavirus diarrhea and the impact and cost-effectiveness of vaccination in Pakistan
    Rheingans, Richard
    Anderson, John D.
    Bagamian, Karoun H.
    Laytner, Lindsey A.
    Pecenka, Clinton J.
    Gilani, Syed Saqlain Ahmad
    Ahmed, Munir
    VACCINE, 2018, 36 (51) : 7780 - 7789
  • [34] Dynamic Modeling of Cost-effectiveness of Rotavirus Vaccination, Kazakhstan
    de Blasio, Birgitte Freiesleben
    Flem, Elmira
    Latipov, Renat
    Kuatbaeva, Ajnagul
    Kristiansen, Ivar-Sonbo
    EMERGING INFECTIOUS DISEASES, 2014, 20 (01) : 29 - 37
  • [35] Cost-effectiveness of rotavirus vaccination in the Philippines: A modeling study
    Villanueva-Uy, Maria Esterlita T.
    Lam, Hilton Y.
    Aldaba, Josephine G.
    Uy, Tristan Marvin Z.
    Valverde, Haidee A.
    Silva, Maria Wilda T.
    Mooney, Jessica
    Clark, Andrew
    Pecenka, Clint
    VACCINE, 2021, 39 (48) : 7091 - 7100
  • [36] Potential impact and cost-effectiveness of rotavirus vaccination in Afghanistan
    Anwari, Palwasha
    Debellut, Frederic
    Pecenka, Clint
    Parwiz, Sardar M.
    Clark, Andrew
    Groman, Devin
    Safi, Najibullah
    VACCINE, 2018, 36 (51) : 7769 - 7774
  • [37] Cost-effectiveness analysis of routine rotavirus vaccination in Brazil
    de Soarez, Patricia Coelho
    Valentim, Joice
    Christovam Sartori, Ana Marli
    Dutilh Novaes, Hillegonda Maria
    REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH, 2008, 23 (04): : 221 - 230
  • [38] Cost-effectiveness analysis of rotavirus vaccination programme in the UK
    Largeron, N.
    Trichard, M.
    Miadi-Fargier, H.
    Trancard, A.
    D'Ausilio, A.
    Chicoye, A.
    VALUE IN HEALTH, 2006, 9 (06) : A243 - A244
  • [39] Cost-effectiveness of mass vaccination with a rotavirus vaccine in the Netherlands
    Al, M. J.
    Goossens, L.
    Hovels, A. M.
    Michielsen, C. P.
    Standaert, B. A.
    VALUE IN HEALTH, 2006, 9 (06) : A304 - A304
  • [40] Impact of transmission dynamics on the cost-effectiveness of rotavirus vaccination
    Shim, Eunha
    Galvani, Alison P.
    VACCINE, 2009, 27 (30) : 4025 - 4030